A Latif1, A Ghafoor1, A Wali2, R Fatima1, Mahboob Ul-Haq1, A Yaqoob1, Z Abdullah3, H Najmi4, N M Khan1. 1. National Tuberculosis Control Programme, Pakistan, Islamabad, Pakistan. 2. Provincial Tuberculosis Control Programme, Balochistan, Quetta, Pakistan. 3. Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan. 4. Sukh Initiative, Aman Health Care Services, Aman Foundation, Karachi, Pakistan.
Abstract
Settings: All hospitals managing drug-resistant tuberculosis (DR-TB) according to national guidelines in Pakistan. Objectives: To assess the effect of diabetes mellitus (DM) and factors associated with unfavourable outcomes in DR-TB. Methods: A cross-sectional study based on a retrospective record review of patients enrolled on DR-TB treatment from 2010 to 2014 in Pakistan. DR-TB data reported to Pakistan's National TB Control Programme on a monthly basis were used for the study. Result: Among 5811 patients enrolled on second-line drugs, 8.8% had DM. Overall, 68.9% had favourable outcomes. No association was found between DM and DR-TB treatment outcomes (risk ratio 0.90, 95%CI 0.74-1.05). Unfavourable outcomes were more frequent among DR-TB patients with human immunodeficiency virus (HIV) co-infection (OR 11.58, 95%CI 2.20-60.72), extensively drug-resistant TB patients (OR 5.36, 95%CI 1.00-28.72), patients with exposure to both first-line and second-line anti-tuberculosis drugs (OR 2.45, 95%CI 1.21-4.97) and those with a previous history of treatment in the private sector (OR 1.53, 95%CI 1.16-2.02). Conclusion: Although there were limitations to correctly measuring DM and its management, DM appears not to be a risk factor for unfavourable outcomes in DR-TB patients in our study. DR-TB and HIV co-infection, second-line drug resistance and history of treatment in the private sector were nevertheless more frequently associated with adverse outcomes.
Settings: All hospitals managing drug-resistant tuberculosis (DR-TB) according to national guidelines in Pakistan. Objectives: To assess the effect of diabetes mellitus (DM) and factors associated with unfavourable outcomes in DR-TB. Methods: A cross-sectional study based on a retrospective record review of patients enrolled on DR-TB treatment from 2010 to 2014 in Pakistan. DR-TB data reported to Pakistan's National TB Control Programme on a monthly basis were used for the study. Result: Among 5811 patients enrolled on second-line drugs, 8.8% had DM. Overall, 68.9% had favourable outcomes. No association was found between DM and DR-TB treatment outcomes (risk ratio 0.90, 95%CI 0.74-1.05). Unfavourable outcomes were more frequent among DR-TBpatients with human immunodeficiency virus (HIV) co-infection (OR 11.58, 95%CI 2.20-60.72), extensively drug-resistant TBpatients (OR 5.36, 95%CI 1.00-28.72), patients with exposure to both first-line and second-line anti-tuberculosis drugs (OR 2.45, 95%CI 1.21-4.97) and those with a previous history of treatment in the private sector (OR 1.53, 95%CI 1.16-2.02). Conclusion: Although there were limitations to correctly measuring DM and its management, DM appears not to be a risk factor for unfavourable outcomes in DR-TBpatients in our study. DR-TB and HIV co-infection, second-line drug resistance and history of treatment in the private sector were nevertheless more frequently associated with adverse outcomes.
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Int J Surg Date: 2014-07-18 Impact factor: 6.071
Authors: A Khaliaukin; A M V Kumar; A Skrahina; H Hurevich; V Rusovich; J Gadoev; D Falzon; M Khogali; P de Colombani Journal: Public Health Action Date: 2014-10-21
Authors: William A Wells; Colin Fan Ge; Nitin Patel; Teresa Oh; Elizabeth Gardiner; Michael E Kimerling Journal: PLoS One Date: 2011-05-04 Impact factor: 3.240
Authors: Matthew J Magee; Russell R Kempker; Maia Kipiani; Nestani Tukvadze; Penelope P Howards; K M Venkat Narayan; Henry M Blumberg Journal: PLoS One Date: 2014-04-15 Impact factor: 3.240
Authors: Joseph Baruch Baluku; Bridget Nakazibwe; Joshua Naloka; Martin Nabwana; Sarah Mwanja; Rose Mulwana; Mike Sempiira; Sylvia Nassozi; Febronius Babirye; Carol Namugenyi; Samuel Ntambi; Sharon Namiiro; Felix Bongomin; Richard Katuramu; Irene Andia-Biraro; William Worodria Journal: J Clin Tuberc Other Mycobact Dis Date: 2021-01-27
Authors: B Diarra; M Tolofoudie; Y S Sarro; A C G Togo; S Bane; I Nientao; A B Cisse; M Kone; A Somboro; B Degoga; F Diallo; G Coulibaly; O Kodio; M Sanogo; B Kone; S Diabate; B Baya; A Kone; D Dabitao; M Maiga; M Belson; S Dao; I I Maiga; R L Murphy; S Siddiqui; Y Toloba; B Konate; S Doumbia; B C de Jong; S Diallo Journal: J Clin Tuberc Other Mycobact Dis Date: 2019-11-01